Sort
16,300 grants matching “fatty liver disease”
Amino Acids and Pediatric Hepatic Steatosis
$883,007Robert R Wolfe · Amino Company Llc, The · R44 · FY2023 · DK
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
$880,013David W Crabb · Indiana University Indianapolis · U01 · FY2013 · AA
CVD in American Indians Study and Data Management Center and OK Field Center
$879,647Elisa Lee · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2014 · HL
Mediators of fatty liver disease during HIV/SIV and cART treatment
$879,420Donald L Sodora · Seattle Children'S Hospital · R01 · FY2021 · AI
Mediators of fatty liver disease during HIV/SIV and cART treatment
$879,420Donald L Sodora · Seattle Children'S Hospital · R01 · FY2022 · AI
Overcoming neurogenic âmeta-inflammationâ to promote recovery after spinal cord injury
$877,540Phillip G Popovich · Ohio State University · R35 · FY2019 · NS
Lipids in Brain Disease and Neuroinflammation: Animal Models
$876,974Stanley I Rapoport · National Institute On Aging · ZIA · FY2012 · AG
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
$875,957Mary Christine Playdon · Utah State Higher Education System--University Of Utah · U01 · FY2025 · CA
Nuclear Receptor Control of T Cell Function in Discrete Intestinal Microenvironments
$874,967Mark Scott Sundrud · Scripps Florida · R01 · FY2021 · AI
The effects of orange juice compared with sugar-sweetened beverage on risk factors and metabolic processes associated with the development of cardiovascular disease and type 2 diabetes
$874,671Kimber Lee Stanhope · University Of California At Davis · R01 · FY2021 · HL
Adverse metabolic effects of dietary sugar _ Ad libitum vs energy-balanced diets
$874,451Peter J Havel · University Of California At Davis · R01 · FY2017 · HL
Three-dimensional maps of senescence in the human pancreas
$874,056Pei-Hsun Wu · Johns Hopkins University · UH3 · FY2025 · CA
Avoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWH
$873,988Suman Srinivasa · Massachusetts General Hospital · R01 · FY2020 · HL
Mediators of fatty liver disease during HIV/SIV and cART treatment
$873,771Donald L Sodora · Seattle Children'S Hospital · R01 · FY2020 · AI
Three-dimensional maps of senescence in the human pancreas
$873,648Pei-Hsun Wu · Johns Hopkins University · UH3 · FY2024 · CA
Lipidomics Biomarkers Link Sleep Restriction to Adiposity Phenotype, Diabetes, and Cardiovascular Risk
$873,305Bruce S Kristal · Brigham And Women'S Hospital · R01 · FY2018 · HL
Maternal High Fat Diet and Melanocortin System in Offspring
$873,090Kevin L Grove · Oregon Health & Science University · R01 · FY2009 · DK
Ethnicity and fat deposition in obesity-related disease in youth
$872,724Vicente Gilsanze · University Of Southern California · P60 · FY2008 · MD
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
$871,604Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2014 · DK
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
$871,014Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2015 · DK
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV
$869,817Suneil Krishna Koliwad · University Of California, San Francisco · R01 · FY2020 · DK
Using resistance training to reduce metabolic and cardiovascular disease risk in
$869,623Christian Roberts · University Of Southern California · P60 · FY2011 · MD
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$866,441Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Aging Intervention Program
$866,420Rafael De Cabo · National Institute On Aging · ZIA · FY2023 · AG
Early Life Social, Environmental, and Nutritional Determinants of Disease (ELSEND)
$865,919Michael I Goran · Children'S Hospital Of Los Angeles · P50 · FY2024 · MD